There are over 7000 diseases that affect 1:2000 people
The genetic causes of these diseases are often known
“Orphan drug” legislation means an easier path to patients
The Market
2024: £130 Billion, 2030: £250 Billion
Long-term CAGR 13.4%
Rapid growth due to awareness, biotech advances, and legislation
Under-served. Fewer patients with these rare genetic disorders makes it harder to recruit people for clinical trials and to make a profit developing treatments
The Competition
Increasing activity in this space for small molecules
Gene therapy shows promise, but post-natal treatment is often too late
Strong, experienced team
Fast, inexpensive platform utilizing Drosophila and other rapid, affordable, and innovative screening methods means we can work at a large scale
Favorable IP terms with the University of Glasgow
Unique UK/China partnership for pre-clinics and clinics